CD276 and non-small cell lung carcinoma: Enoblituzumab is an anti-B7-H3 mAb currently evaluated as monotherapy or in combinatorial regimens in three clinical trials in patients with NSCLC and other solid tumors (NCT02381314, NCT01391143, NCT02475213).